Browse THOC5

Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Shuttles between nucleus and cytoplasm.
Domain PF09766 Fms-interacting protein
Function

Acts as component of the THO subcomplex of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and which specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. THOC5 in conjunction with ALYREF/THOC4 functions in NXF1-NXT1 mediated nuclear export of HSP70 mRNA; both proteins enhance the RNA binding activity of NXF1 and are required for NXF1 localization to the nuclear rim. Involved in transcription elongation and genome stability. Involved in alternative polyadenylation site choice by recruiting CPSF6 to 5' region of target genes; probably mediates association of the TREX and CFIm complexes.; FUNCTION: Regulates the expression of myeloid transcription factors CEBPA, CEBPB and GAB2 by enhancing the levels of phosphatidylinositol 3,4,5-trisphosphate. May be involved in the differentiation of granulocytes and adipocytes. Essential for hematopoietic primitive cell survival and plays an integral role in monocytic development.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0006353 DNA-templated transcription, termination
GO:0006354 DNA-templated transcription, elongation
GO:0006369 termination of RNA polymerase II transcription
GO:0006397 mRNA processing
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0008380 RNA splicing
GO:0010948 negative regulation of cell cycle process
GO:0015931 nucleobase-containing compound transport
GO:0019058 viral life cycle
GO:0030099 myeloid cell differentiation
GO:0030224 monocyte differentiation
GO:0031123 RNA 3'-end processing
GO:0031124 mRNA 3'-end processing
GO:0031570 DNA integrity checkpoint
GO:0032784 regulation of DNA-templated transcription, elongation
GO:0032786 positive regulation of DNA-templated transcription, elongation
GO:0035162 embryonic hemopoiesis
GO:0044766 multi-organism transport
GO:0045786 negative regulation of cell cycle
GO:0046784 viral mRNA export from host cell nucleus
GO:0046794 transport of virus
GO:0048568 embryonic organ development
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0051028 mRNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0060215 primitive hemopoiesis
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
GO:0075733 intracellular transport of virus
GO:1901976 regulation of cell cycle checkpoint
GO:1901977 negative regulation of cell cycle checkpoint
GO:1902579 multi-organism localization
GO:1902581 multi-organism cellular localization
GO:1902583 multi-organism intracellular transport
GO:1903131 mononuclear cell differentiation
GO:2000001 regulation of DNA damage checkpoint
GO:2000002 negative regulation of DNA damage checkpoint
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
Molecular Function GO:0003729 mRNA binding
Cellular Component GO:0000346 transcription export complex
GO:0000347 THO complex
GO:0000445 THO complex part of transcription export complex
GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa03013 RNA transport
Reactome R-HSA-109688: Cleavage of Growing Transcript in the Termination Region
R-HSA-74160: Gene Expression
R-HSA-112296: Post-Elongation Processing of Intron-Containing pre-mRNA
R-HSA-76044: Post-Elongation Processing of the Transcript
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-73856: RNA Polymerase II Transcription Termination
R-HSA-72202: Transport of Mature Transcript to Cytoplasm
R-HSA-159236: Transport of Mature mRNA derived from an Intron-Containing Transcript
R-HSA-72187: mRNA 3'-end processing
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between THOC5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of THOC5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of THOC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1140.665
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.250.892
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0210.988
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0190.955
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2660.893
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3840.883
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1610.685
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0340.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3980.811
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5380.662
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8120.675
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0160.785
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of THOC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of THOC5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of THOC5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by THOC5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of THOC5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of THOC5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between THOC5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTHOC5
NameTHO complex 5
Aliases PK1.3; KIAA0983; Fmip; fSAP79; functional spliceosome-associated protein 79; C22orf19; chromosome 22 open re ......
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting THOC5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.